Everist Health
Ann Arbor · Founded 2002
About Everist Health
Everist Health, Inc. (EGI) is a personalized medicine company, which develops and commercializes medically unique diagnostics, prognostics and therapeutic selection technologies. EGI is focused on rapidly growing disease areas with major unmet needs, including cancer, cardiovascular disease and metabolic disease (e.g. diabetes). Mission Everist Health is driving growth by developing innovative prognostics with potential for substantive impact on medical and financial outcomes. Our strategy centers on proprietary research and development, targeted acquisitions, and in-licensing. Everist Health is currently developing a range of products aimed at improving treatment outcomes in: • Cardiovascular Disease (CVD) • Metabolic Diseases (e.g. diabetes) • Neurodegenerative Diseases (e.g. Alzheimer’s and Parkinson’s disease) Description Our mission is developing and commercializing molecular assays and sensor technology aimed at improving patient outcomes and cost-efficiency through better-informed clinical decisions. At the core of our success is our evolutionary and proprietary (patent-protected) Evolver technology platform, which accelerates the development of innovative molecular prognostic tests. Utilizing the Evolver technology, Everist Health has developed the AngioDefender CVD diagnostic system; the world’s first non-invasive device that successfully combines patent protected non-invasive sensor technology and a sophisticated software algorithm to quickly and cost effectively help physicians assess the presence of early-stage CVD and atherosclerosis.
Company Facts
- Founded: 2002
- Legal name: Everist Genomics, Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $12.5M
- Last round: Series Unknown (Sep 2012)
- Website: everisthealth.com
- Phone: +1 855-383-7478
Social Profiles
Canonical: https://fsome.com/organization/everist-health-8442751 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.